Early prediction of treatment outcome for lenvatinib using (18)F-FDG PET/CT in patients with unresectable or advanced thyroid carcinoma refractory to radioiodine treatment: a prospective, multicentre, non-randomised study

BACKGROUND: Lenvatinib is widely used to treat unresectable and advanced thyroid carcinomas. We aimed to determine whether (18)F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) performed 1 week after lenvatinib treatment initiation could predict treatment outcomes....

Descripción completa

Detalles Bibliográficos
Autores principales: Takeuchi, Satoshi, Hirata, Kenji, Magota, Keiichi, Watanabe, Shiro, Moku, Rika, Shiiya, Akihiko, Taguchi, Jun, Ariga, Shin, Goda, Tomohiro, Ohhara, Yoshihito, Noguchi, Takurou, Shimizu, Yasushi, Kinoshita, Ichiro, Honma, Rio, Tsuji, Yasushi, Homma, Akihiro, Dosaka-Akita, Hirotoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10352209/
https://www.ncbi.nlm.nih.gov/pubmed/37460834
http://dx.doi.org/10.1186/s13550-023-01019-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10352209/
https://www.ncbi.nlm.nih.gov/pubmed/37460834
http://dx.doi.org/10.1186/s13550-023-01019-9

Ejemplares similares